IL36G and non-small cell lung carcinoma: In this context, our preclinical data with anti‐IL‐36γ to neutralize IL‐36γ or elastase inhibitor to block IL‐36γ maturation have demonstrated that targeting IL‐36γ significantly alleviated NSCLC progression and prolonged the survival of KL or KP mice after tumor induction.